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Abstract
OBJECTIVES: The full potential of stereotactic body radiation therapy (SBRT), in the treatment of unresectable intra-
hepatic malignancies, has yet to be realized as our experience is still limited. Thus, we evaluated SBRT outcomes
for primary and metastatic liver tumors, with the goal of identifying factors that may aid in optimization of therapy.
METHODS: From 2005 to 2010, 62 patients with 106 primary and metastatic liver tumors were treated with SBRT to a
median biologic effective dose (BED) of 100 Gy (42.6–180). The majority of patients received either three (47%) or
five fractions (48%). Median gross tumor volume (GTV) was 8.8 cm3 (0.2–222.4). RESULTS: With a median follow-
up of 18 months (0.46–46.8), freedom from local progression (FFLP) was observed in 97 of 106 treated tumors,
with 1- and 2-year FFLP rates of 93% and 82%. Median overall survival (OS) for all patients was 25.2 months, with
1- and 2-year OS of 81% and 52%. Neither BED nor GTV significantly predicted for FFLP. Local failure was associated
with a higher risk of death [hazard ratio (HR) = 5.1, P = .0007]. One Child-Pugh Class B patient developed radiation-
induced liver disease. Therewere no other significant toxicities.CONCLUSIONS: SBRT provides excellent local control
for both primary and metastatic liver lesions with minimal toxicity. Future studies should focus on appropriate selec-
tion of patients and on careful assessment of liver function to maximize both the safety and efficacy of treatment.
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Introduction
The majority of patients with intrahepatic cancer are ineligible for
curative resection because of impaired liver function; multiple, large,
or centrally located lesions; or medical comorbidities. Alternative
treatment methods have emerged, among which radiofrequency
ablation (RFA) is the most widely used and offers a high rate of local
control. However, large liver lesions and lesions located near major
blood vessels, the main biliary tract, or at the dome are not amenable
to this treatment. In addition, RFA is an invasive procedure requiring
anesthesia that has been associated with significant complications
such as pneumothorax and bleeding [1]. Thus, patients with unresect-
able disease that cannot be addressed by local therapies such as RFA
may benefit from non-invasive treatments involving radiation therapy.
Although treating liver tumors with external beam radiation has
historically been limited by toxicity [2], we have previously demon-
strated long-term local control and possibly prolonged overall sur-
vival (OS) with carefully planned fractionated radiotherapy with
low risk of complications [3]. Stereotactic body radiation therapy
(SBRT) now can be used to precisely target small liver tumors: im-
proved immobilization, localization, and compensation for respiratory
movement allow for the delivery of large, focused fractions of radia-
tion, while minimizing dose to the remaining liver. Several small stud-
ies have demonstrated that SBRT is an effective and safe means of
local treatment [4–9]. However, experience with SBRT for liver tumors
is still limited. In this study, which is the largest to date, we evaluated
the effects of biologic effective dose (BED), tumor size, and histology
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on local control and survival after SBRT in patients with primary and
metastatic liver tumors. In particular, we aimed to determine if there is a
subset of patients who may benefit from further treatment intensification.
Materials and Methods
Eligibility
As part of an Institutional Review Board–approved retrospective
review, we searched the University of Michigan Radiation Oncology
database to identify patients who received SBRT for primary or meta-
static liver tumors between 2005 and 2010. Information was available
for 62 patients with a total of 106 treated liver tumors. In general,
patients had liver lesions that were unresectable, not amenable to
RFA, or had progressed after RFA. In one case, the patient refused
surgical resection.
Radiation Treatment
All patients underwent computed tomography (CT) simulation and
were immobilized in the supine position with a customized vacuum
body mold. In general, an active breathing control (ABC) device was
used to control breathing-related tumor motion. For patients unable to
tolerate ABC, 4DCT or a set of maximal inhalation and exhalation
breath hold CTs was used to generate an internal target volume. When
the target lesion was not readily apparent on the contrast-enhanced
planning CT images, the planning data set was registered to a pre-
treatment diagnostic magnetic resonance imaging study, using a mutual
information algorithm in our in-house treatment planning system,
UMPLAN, to facilitate target delineation [10]. The gross tumor
volume (GTV) for ABC cases and the internal target volume for
free-breathing cases were expanded by a 5-mm radial and 8-mm cranio-
caudal margin for the planning target volume (PTV) [11]. SBRT was
planned and delivered using three-dimensional conformal techniques
with multiple (typically ≥8), non-opposed, non-coplanar static 6 or
16 MV beams. Radiation dose was prescribed to the isodose surface
covering 99.5% of the PTV, typically 75% to 85% of the maximum
PTV dose. The majority of patients received either three or five frac-
tions (47% and 48%, respectively), with 20 Gy × 3 (31%) and 10 Gy ×
5 (39%) comprising the most common dose fractionation schemes.
Generally, patients received five fractions due to the proximity of organs
at risk. Dose limits to the duodenum, stomach, and heart were 24,
22.5, and 30 Gy, respectively, while <30 cm3 of the chest wall was per-
mitted to receive ≥30 Gy for patients treated with three-fraction
SBRT. These limits were 30, 27.5, 52.5, and 35 Gy for patients treated
with five fractions. Three early patients received a single fraction of
24 Gy (n = 2) or 26 Gy (n = 1).
Daily image guidance and positioning was performed with either
orthogonal X-rays or cone beam CT imaging. X-ray localization
involved alignment of one to three percutaneously placed intrahepatic
fiducial markers in the vicinity of the lesion for 38 patients (52 lesions),
whereas cone beam CT alignment included markers or landmarks
such as large liver vessels and surface features of the liver for the
remaining patients.
Follow-up
Patients were evaluated at 1 and 3 months after completion of
SBRT and then every 3 to 6 months thereafter. Follow-up visits typi-
cally consisted of a history and physical examination, tumor marker
assessment, serum liver enzymes, and imaging with CT, magnetic
resonance imaging, or positron emission tomography (PET). Follow-
up imaging was reviewed by a radiologist and a radiation oncologist.
Treatment response was assessed for each treated lesion and scored
using the Response Evaluation Criteria in Solid Tumors. Local recur-
rence was scored as in-field or marginal failure [12]. New lesions were
also documented.
Evaluation of Response and Statistical Analysis
The primary end point was freedom from local progression
(FFLP), defined as the absence of new or progressive lesions within
or at the margin of the PTV. Secondary end points were freedom
from any progression, OS, and toxicity. Freedom from any progres-
sion was defined as freedom from any local, distant intrahepatic, or
distant extrahepatic progression. FFLP, freedom from any progres-
sion, and OS were estimated using the Kaplan-Meier method. Most
analyses were conducted at the lesion level, with each lesion con-
tributing a unique observation for analysis. Dose analyses were per-
formed using BED, a standard method of accounting for differences
in dose per fraction and total dose when comparing treatments. Sur-
vival end points were calculated as time from the start of SBRT. The
robust sandwich variance estimate was used to account for correla-
tion between multiple lesions within a subject [13]. A modified score
test using this variance estimate was used to test for significance of
predictors in Cox regression models. To assess whether local failure
was predictive of OS, it was included as a time-dependent covariate
in a Cox regression model for OS. This analysis was performed at
the patient level so OS time was measured as the time from the start
of radiation therapy for the first treated lesion until death or loss to
follow-up. The time-dependent covariate was an indicator variable
(yes or no) for failure of any treated lesion. The software package
SAS (V9.2, Cary, NC) was used for analysis.
Results
Patient and Treatment Characteristics
Patient characteristics are presented in Table 1. In total, there were
62 patients with 106 unique lesions treated with SBRT and assessable
for outcome analysis. Median follow-up for all lesions was 18 months
(range, 0.46–46.8) and for alive patients 12.4 months (range, 1–47).
Metastatic tumors comprised the majority of lesions (65%), with
colorectal (CRC), breast, and esophageal primaries accounting for
23%, 8%, and 8% of all lesions, respectively. Hepatocellular carcinoma
(HCC) represented the most common lesion overall, constituting 29%
of all lesions.
Patients were heavily pretreated: 51% of cases received one or more
prior form of liver-directed therapy, including transarterial chemo-
embolization, RFA, fractionated radiotherapy, intra-arterial chemo-
therapy, and surgical resection, and 54% received one or more prior
systemic therapy regimen.
Clinical Outcomes
FFLP was observed in 97 of 106 treated lesions with 1- and 2-year
FFLP rates of 93% and 82%, respectively (Figure 1). On multi-
variate analysis, no correlation was found between FFLP and lesion
size, BED, prior systemic or liver-directed therapy, number of active
liver lesions, or whether the lesion was metastatic or primary. There
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was a trend toward better local control for patients with HCC
compared with colorectal metastases (Figure 2), although this differ-
ence was not significant. For patients with HCC, 1- and 2-year FFLP
rates were 93% and 93%, respectively, while for patients with colo-
rectal metastases, 1- and 2-year FFLP rates were 86% and 67% (HR =
0.203, P = .0827). Of the 31 HCC lesions, one failed locally, 19 failed
elsewhere in the liver, and 5 had distant progression. Of the 24 CRC
lesions, 6 failed locally, 14 failed elsewhere in the liver, and 17 had
distant progression. Of all local failures, two were marginal and seven
were in-field (Table 2). One marginal recurrence was in a patient with
metastatic breast cancer, who developed four new liver metastases
8 months after SBRT to 36 Gy in three fractions. Her marginal recur-
rence occurred 14 months after SBRT, in the setting of continued liver
progression. She also had received multiple prior systemic therapies and
had active extrahepatic disease at the start of treatment. The other
marginal recurrence was in an HCC patient who had been treated with
two surgical resections, as well as five transarterial chemoembolization
(TACE) procedures before SBRT to 50 Gy in five fractions. Sub-
sequent to SBRT, he underwent two additional TACE procedures
for new out-of-field tumors. His marginal recurrence, 2 years after
SBRT, occurred in the setting of a massive, diffuse recurrence through-
out the liver, bones, spleen, and peritoneum. Both patients were treated
with ABC, with standard PTV margins, as described above. Image-
guided radiotherapy (IGRT) consisted of alignment of fiducial markers
with cone beam computed tomography (CBCT).
Because the local failure rate for patients with CRC was higher
than for other groups of patients, we also reviewed these failures in
detail. The six CRC failures occurred in four patients, all of whom
had received prior systemic therapy and three of whom had active
extrahepatic disease at the start of radiation treatment. All had distant
progression before local recurrence after SBRT. One patient failed in
one of three treated lesions and developed new intrahepatic lesions.
Two patients each progressed in two lesions, one with concurrent
new lesions and the other with a massive, diffuse liver recurrence.
One of the four CRC patients had only one active liver lesion at
the time of treatment, but this patient also had a massive, diffuse liver
recurrence and lung metastases. Colorectal metastases actually received
a significantly higher BED (mean of 133 vs 109, P = .03) than HCC
tumors, despite lower FFLP, and no recurrences were marginal. Median
OS for all patients was 25.2 months, with 1- and 2-year OS of 81%
and 52%, respectively (Figure 3). Survival was greater among patients
with metastatic compared to primary lesions (2-year OS of 63% vs
29%, HR = 0.46, P = .02). For patients with metastatic liver lesions,
the presence of active extrahepatic disease yielded significantly worse
survival (2-year OS of 37% vs 83%, HR = 3.8, P = .005). Lesion size,
BED, prior systemic or liver-directed therapy, and number of activeFigure 1. FFLP for treated tumors.
Figure 2. FFLP for HCC and colorectal metastases.
Table 1. Patient and Tumor Characteristics.
No. %
Total No. of patients 62




Primary liver tumors 37 35
Hepatocellular carcinoma 31 29
Intrahepatic cholangiocarcinoma 6 6
Metastatic liver tumors 69 65
Colorectal primary 24 23
Breast primary 9 8
Esophageal primary 8 8
Other primary 28 26











Child-Pugh classification, HCC tumors
Class A (5–6) 22 71
Class B (7–9) 7 23
Class C (10–15) 2 6






Median biologic equivalent dose (BED10)
Median 100
Range 42.6–180
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liver lesions did not influence survival. Four of the seven patients who
experienced local progression died within 5 weeks of local progression.
In a Cox model for OS with presence of local progression as a time-
dependent covariate, the presence of a local failure resulted in a signifi-
cantly increased risk of death (HR = 5.1, P = .0007).
In 104 assessable lesions at last follow-up (1 patient was lost to
follow-up and 1 patient had a liver transplant shortly after treat-
ment), 40 lesions had a sustained objective tumor response according
to Response Evaluation Criteria in Solid Tumors (8 had complete
response; 32 had partial response) and 55 lesions had stable disease.
Nine lesions progressed, in seven patients. One of these lesions was
retreated and progressed later. Freedom from any progression for all
patients was 28% and 15% at 1 and 2 years, respectively.
Assessment for Dose-Response
BED was calculated using the linear quadratic formula with α/β
ratio of 10. For all lesions, the median BED was 100 Gy (range,
42.6–180), with 76% of lesions receiving ≥100 BED. Dose was
not a significant predictor of FFLP in a univariate model. In fact,
eight of nine failures in our series received ≥100 BED, whereas
24 of 25 patients who received <100 BED were controlled locally.
As expected, there was moderate negative correlation between GTV
and BED (Spearman’s rho = −0.45). To account for possible confound-
ing with size, BED and GTV were included together in a multivariate
model. In thismodel, neither GTV (median, 8.8 cm3; range, 0.2–222.4)
nor BED was found to significantly predict FFLP. Among the
patients with larger tumors (>20 cm3, the upper quartile), those
who received >100 BED tended to have a higher FFLP than those who
received =100 Gy, although this trend was not statistically significant.
Toxicity
Overall, patients tolerated treatment well, and all patients com-
pleted therapy without treatment breaks. Only one patient experienced
a serious toxicity, which was the development of radiation-induced liver
disease (RILD), who recovered. This patient had hepatitis C cirrhosis,
Child-Pugh Class B liver disease, and had received multiple prior liver-
directed therapies, including twoRFAs and SBRT.Her 2.87-cm3 tumor
received 45 Gy in five fractions. No gastrointestinal bleeding, rib frac-
ture, or pneumonitis was observed.
Discussion
In this series, we demonstrate that SBRT provides excellent local
control with minimal toxicity for both primary and metastatic liver
tumors, with 1- and 2-year FFLP rates of 93% and 82%, respectively,
and a median OS of 25.2 months. Neither tumor size nor BED was
found to significantly predict FFLP. Our local control rates are con-
sistent with prior SBRT as well as RFA series of primary and meta-
static liver tumors [1,4–9]. The majority of patients in our study had
prior liver-directed and systemic therapies. Despite the inclusion of
patients refractory to multiple lines of treatment, there were only nine
cases (8%) of local progression.
While ourHCC lesions had excellent local control, with 1- and 2-year
FFLP rates of 93% and 93%, our CRC control rate (1- and 2-year
FFLP rates of 86% and 67%) was substantially lower, consistent with
other reports [5,9]. The series on SBRT for primary and metastatic liver
lesions of Wulf et al. found 1- and 2-year local control rates at approx-
imately 90% and 55%, respectively. In fact, all nine of their local fail-
ures occurred in metastatic liver lesions, with six from CRC. They
suggested that dose escalation results in better local control, as 6 of
the 12 CRC patients in their series who received 3 × 10 Gy had local
failure, while none of the 11 CRC patients treated with higher doses
(3 × 12–12.5 or 1 × 26Gy) did. The pooled analysis of Chang et al. also
demonstrated a 55% 2-year local control rate [7], with total dose, dose
per fraction, and BED correlated with local control in multivariate
analysis. A dose effect was not demonstrated in our series, despite using
a variety of dose fractionation schedules since the start of the SBRT
program in 2005. This may have been due to the relatively high overall
doses, with 76% lesions receiving ≥100 BED. However, among
patients with the largest tumors (>20 cm3), those who received higher
dose (>100 Gy) tended to have better FFLP, although not statistically
significant, hinting at a possible correlation limited by a small sample
size and relatively small tumors in our series (median of 9 cm3, com-
pared with 30 cm3 in the pooled analysis of Chang et al.). Treatment
intensification may be necessary for larger tumors, whereas smaller
tumors may be controlled by any large, ablative dose of SBRT. Further-
more, we can rule out a difference in planning, image guidance, or
treatment delivery as the cause of our CRC failures, because all of our
CRC failures were in-field rather than marginal misses. Although we
prioritized dose limits of normal tissues over target coverage, no recur-
rences were observed in regions of rapid dose falloff near normal tissues.
Table 2. Tumor and Treatment Characteristics of Local Failures.
Primary Site BED* (Gy) GTV† (cm3) Location of Failures
1 Colon 100 3 In-field
2 Colon 180 10 In-field
3 Colon 125 4 In-field
4 Colon 180 13 In-field
5 Colon 101 3 In-field
6 Colon 100 19 In-field
7 Pancreas 100 118 In-field
8 Breast 79 47 Marginal
9 Liver (HCC) 100 57 Marginal
*Median BED = 100 Gy.
†Median GTV = 13 cm3.
Figure 3. OS for treated tumors.
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The most likely cause for the relatively higher number of local fail-
ures in CRC patients is that our cohort had biologically aggressive
disease, evidenced by distant failures predating local failures in all
cases, which highlights the need for better patient selection, to iden-
tify patients most likely to benefit from this treatment. Despite high
control rates, survival in this study was lower than with hepatic
resection [14], likely since almost all of these patients were medically
inoperable, with lower than expected OS than those who would have
qualified for surgery, and the more rigorous selection of patients for
surgery. The presence of active extrahepatic disease was found to be a
significant predictor for OS, confirming the importance of proper
patient selection and the need for improved systemic therapy.
Limitations of this study include the retrospective nature, small
patient numbers compared with other disease sites, and variety of pre-
SBRT and post-SBRT systemic and liver-directed therapies. Still, this
is the largest combined series of primary and metastatic liver tumors.
SBRT in our series was well tolerated, with only one case of RILD,
which resolved, suggesting that SBRT may have a more favorable
toxicity profile than RFA, which can result in anesthetic and post-
procedural complications, in addition to bile duct and vessel injuries,
gastrointestinal (GI) perforation, and pneumothorax [1]. Further
study suggests that SBRT may be an alternative to RFA, and this
should be investigated in a prospective clinical trial [15].
On the basis of our case of RILD and the experience of others [9],
patients who are Child-Pugh Class B or who have had previous liver-
directed therapies should be treated with caution. To address these
patients, we are now conducting a phase II study of a new approach
to SBRT for patients at increased risk of toxicity with the aim of
maximizing both the safety and efficacy of treatment for each indi-
vidual patient [16]. Using clearance rates of indocyanine green, a dye
that is taken up from the plasma almost exclusively by hepatic paren-
chymal cells [17], liver function is tested before treatment, as well as
following a partial course of therapy, to assess the liver’s tolerance of
radiotherapy. The remainder of treatment is customized for each
patient based on the change in function. By individualizing dose this
way, we can potentially simultaneously maximize both the safety and
efficacy of treatment.
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